Dr. Andrea Oliverio, MD, MSc
Claim this profileUniversity of Michigan
Studies Contrast-induced Nephropathy
Studies Chronic kidney disease
2 reported clinical trials
3 drugs studied
Affiliated Hospitals
Clinical Trials Andrea Oliverio, MD, MSc is currently running
Pregnancy and Contraception Education
for Chronic Kidney Disease
This pilot study will assess the efficacy of a pregnancy and contraception education decision aid (DA) for patients with chronic kidney disease to support decisions about reproductive health, and will assess feasibility and acceptability of the intervention to inform future Research Project Grant (R01) level studies.
Recruiting1 award N/A
Belimumab + Rituximab
for Kidney Disease
The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with primary membranous nephropathy. Background: Primary membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults. MN affects individuals of all ages and races. The peak incidence of MN is in the fifth decade of life. Primary MN is recognized to be an autoimmune disease, a disease where the body's own immune system causes damage to kidneys. This damage can cause the loss of too much protein in the urine. Drugs used to treat MN aim to reduce the attack by one's own immune system on the kidneys by blocking inflammation and reducing the immune system's function. These drugs can have serious side effects and often do not cure the disease. There is a need for new treatments for MN that are better at improving the disease while reducing fewer treatment associated side effects. In this study, researchers will evaluate if treatment with a combination of two different drugs, belimumab and rituximab, is effective at blocking the immune attacks on the kidney compared to rituximab alone. Rituximab works by decreasing a type of immune cell, called B cells. B cells are known to have a role in MN. Once these cells are removed, disease may become less active or even inactive. However, after stopping treatment, the body will make new B cells which may cause disease to become active again. Belimumab works by decreasing the new B cells produced by the body and, may even change the type of new B cells subsequently produced. Belimumab is approved by the US Food and Drug Administration (FDA) to treat systemic lupus erythematosus (also referred to as lupus or SLE). Rituximab is approved by the FDA to treat some types of cancer, rheumatoid arthritis, and vasculitis. Neither rituximab nor belimumab is approved by the FDA to treat MN. Treatment with a combination of belimumab and rituximab has not been studied in individuals with MN, but has been tested in other autoimmune diseases, including lupus nephritis and Sjögren's syndrome.
Recruiting1 award Phase 212 criteria
More about Andrea Oliverio, MD, MSc
Clinical Trial Related1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Andrea Oliverio, MD, MSc has experience with
- Pregnancy And Contraception Education Decision Aid
- Belimumab
- Rituximab
Breakdown of trials Andrea Oliverio, MD, MSc has run
Contrast-induced Nephropathy
Chronic kidney disease
Chronic Kidney Disease
Nephrotic Syndrome
Lupus Nephropathy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andrea Oliverio, MD, MSc specialize in?
Andrea Oliverio, MD, MSc focuses on Contrast-induced Nephropathy and Chronic kidney disease. In particular, much of their work with Contrast-induced Nephropathy has involved anti-PLA2R positive patients, or patients who are undergoing treatment.
Is Andrea Oliverio, MD, MSc currently recruiting for clinical trials?
Yes, Andrea Oliverio, MD, MSc is currently recruiting for 2 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Andrea Oliverio, MD, MSc has studied deeply?
Yes, Andrea Oliverio, MD, MSc has studied treatments such as Pregnancy and Contraception Education Decision Aid, Belimumab, Rituximab.
What is the best way to schedule an appointment with Andrea Oliverio, MD, MSc?
Apply for one of the trials that Andrea Oliverio, MD, MSc is conducting.
What is the office address of Andrea Oliverio, MD, MSc?
The office of Andrea Oliverio, MD, MSc is located at: University of Michigan, Ann Arbor, Michigan 48109 United States. This is the address for their practice at the University of Michigan.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.